Purpose The observation that the orphan drug dichloroacetate (DCA) selectively promotes mitochondria-regulated apoptosis and inhibits tumour growth in preclinical models by shifting the glucose metabolism in cancer cells from anaerobic to aerobic glycolysis attracted not only scientists', clinicians' but also patients' interests and prompted us to further evaluate DCA effects against paediatric malignancies. Methods The effects of DCA on mitochondrial membrane potential (DWm), cell viability and induction of apoptosis were evaluated in paediatric tumour cell lines and the non-malignant cell line HEK293. In addition, combinations of DCA with the standard anticancer drugs cisplatin, doxorubicin, and temozolomide were tested and intra-and extra-cellular platinum species analysed. Results DCA selectively induced phosphatidylserine externalisation and reduced DWm in paediatric tumour cells compared to HEK293 cells, but DCA concentrations B10 mmol/L only moderately inhibited the growth of 18 paediatric tumour cell lines. DCA neither influenced the in vitro stability of cisplatin nor the cellular cisplatin uptake, but it abrogated the cytotoxicity of cisplatin in 7 out of 10 cell lines. DCA also affected the cytotoxicity of doxorubicin but did not influence the cytotoxicity of temozolomide. Despite phosphatidylserine externalisation, DCA failed to activate caspase 3/7 and, moreover, suppressed caspase 3/7 activation by cisplatin and doxorubicin. Conclusions Our results indicate that apart from the intriguing effects of DCA on the glucose metabolism of cancer cells, the use of DCA for cancer treatment has to be evaluated carefully. Moreover, compassionate use of the orally available drug by patients with cancer themselves without medical supervision is strongly discouraged at present.
Introduction
Anaerobic glycolysis (also known as Warburg Effect) is a common feature of cancer cells. In contrast to normal cells, which metabolise most of their pyruvate via acetyl-CoA and the Krebs cycle in their mitochondria, malignant cells shift their pyruvate catabolism from this oxygen-dependent pathway to cytoplasmatic, anaerobic glycolysis [1] [2] [3] . The generic drug dichloroacetate (DCA) stimulates the activity of the enzyme pyruvate dehydrogenase (PDH) through inhibition of the enzyme pyruvate dehydrogenase kinase (PDK) [4, 5] . Activation of PDH shifts the catabolism of pyruvate from oxygen-independent lactate formation to oxygen-dependent acetyl-CoA formation. The irreversible conversion of pyruvate into acetyl-CoA results in a sustained activation of the Krebs cycle, which in turn increases the production of reactive oxygen species (ROS) in the mitochondria. The increased concentrations of ROS damage the redox sensitive complex I, inhibit H? efflux and decrease the mitochondrial membrane potential (DWm). This decrease of DWm again facilitates the opening of the DWm-sensitive mitochondrial transition pores (MTP) and promotes the efflux of cytochrome c (cyt c) and apoptosis-inducing factor (AIF). In addition, ROS translocated to the cytoplasm reduce the tonic inhibition of caspases by dilating Kv1.5 potassium ion channels and-in a positive feedback loop-by increasing the expression of Kv1.5 potassium channels [6] . DCA was shown to inhibit cell growth over a wide range of tumour cells. In preclinical studies, DCA reduced DWm, induced apoptosis and inhibited the proliferation of breast cancer, endometrial cancer, prostate cancer, non-small cell lung cancer and glioblastoma cell lines [6] [7] [8] . In preclinical in vivo studies, DCA reduced the growth of non-small cell lung cancer xenografts and significantly diminished the number of lung metastasis in a rat mammary adenocarcinoma metastasis model [6, 9] . In addition, reversal of the glycolytic phenotype reduced the growth of pancreas tumour xenografts [10] .
Since non-malignant cells usually do not use anaerobic glycolysis for energy production, DCA had no effect on proliferation and induction of apoptosis in non-malignant cells [6, 7] . Thus, selective modulation of the glycolytic phenotype of cancer cells by DCA seems to be a promising approach for an effective and tolerable treatment of cancer [11, 12] . For its ability to favour glucose metabolism by aerobic glycolysis, DCA has been used for more than 30 years for the treatment of lactate acidosis and inherited mitochondrial diseases in adults as well as in children [13] [14] [15] . Though clinical trials in humans with cancer had yet to be performed, DCA was celebrated as the magic bullet against cancer by the public press further stimulating the attraction of DCA for patients with cancer. Patients with cancer opt for this orally available drug and can purchase it from several distributors [16] . The promising preclinical results against adult malignancies along with the availability of safety data in adults and children provided a strong rationale for the evaluation of DCA against paediatric malignancies. Here, we report on the effects of DCA against a panel of 18 immortal tumour cell lines representing six of the most common and aggressive paediatric tumour types. Since DCA by decreasing DWm is supposed to promote mitochondria-mediated apoptosis, we also analysed the combination of DCA with standard anticancer drugs.
Methods

Reagents
DCA and temozolomide were purchased from TOCRIS Bioscience (TOCRIS Cookson Ltd., Bristol, UK). Both drugs were dissolved in DMSO (Sigma-Aldrich, Deisenhofen, Germany) and further diluted with complete cell culture medium. Cisplatin was purchased from GryPharma GmbH (Kirchzarten, Germany), and doxorubicin was obtained from Pharmacia GmbH (Karlsruhe, Germany). 5 U/L penicillin, 100 mg/L streptomycin, and 25 mg/L amphotericin B (GibcoBRL cell culture, Invitrogen GmbH, Karlsruhe, Germany). Cells were cultured at 37°C in a humidified atmosphere with 5% CO 2 . The Ewing sarcoma cell lines were grown on tissue culture flasks coated with collagen.
Cell viability assays
Screening of cell viability was determined by the wellacknowledged MTT assay and the CellTiter-Glo TM cell viability assay (Promega, Mannheim, Germany). While the MTT assay detects viable cells via reduction of the yellow 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT; Sigma, Deisenhofen, Germany) to a purple formazan dye by mitochondrial aldehyde dehydrogenases, CellTiterGlo TM identifies viable cells via their ATP content. The formation of the purple formazan dye correlates with the amount of viable cells and was quantified spectrophotometrically at a wavelength of 560 nm with an Ascent Multiscan Ò microplate reader (Thermo Fisher Scientific, Langenselbold, Germany). The ATP released from viable cells after lysis was detected via a luminescent dye, which was quantified with the Fluoroskan Ascent FL (Thermo Fisher Scientific, Langenselbold, Germany).
Cells were exposed to serial drug dilutions as indicated in the text. The measured absorptions/luminescence were used to calculate the rate of cell viability compared to untreated controls. In each experiment, each concentration was tested in quadruplets and all experiments were repeated at least three times.
Assessment of apoptosis by phosphatidylserine externalisation and DWm
Cells were seeded at 2 9 10 5 cells per well into six-well plates and left overnight to adhere and resume exponential cell growth. Then DCA was added and cells were incubated for another 24- . Fluorescenceactivated cells were analysed on a FACScan flow cytometer (Becton-Dickinson, San Jose, CA, USA), and data were analysed using the CellQuest software (BectonDickinson).
Evaluation of caspase 3/7 activation
Caspase activation was determined using the caspase-Glo Ò 3/7 assay supplied by Promega (Mannheim, Germany) according to the manufacturer's instructions. Cells (5 9 10 4 cells/well) were seeded in white-walled 96-well plates (Greiner Bio-One GmbH, Solingen, Germany) treated with DCA, cisplatin, and doxorubicin as indicated. Luminescence was measured with the Fluoroskan Ascent FL (Thermo Scientific, Langenselbold, Germany).
Quantification of cellular platinum concentrations
The total platinum concentration in cells and cell culture medium was determined by inductively coupled plasmaoptical emission spectroscopy (ICP-OES) using a Spectro CIROS instrument (Spectro Analytical Instruments, Kleve, Germany). Platinum emission was detected simultaneously at two different emission lines (214.40 and 299.97 nm). Cells and cell culture medium were analysed separately. The cells were dissolved in nitric/hydrochloric acid (1/3, v/v) and diluted with bidistilled water. The cell culture medium solutions were diluted with 1% nitric acid prior to analysis.
Quantification of cisplatin in cell culture medium Cisplatin in cell culture medium was determined by application of liquid chromatography coupled to inductively coupled plasma-mass spectrometry (LC/ICP-MS) using an Agilent model 1200 HPLC and an Agilent 7500 ICP-MS (both from Agilent Technologies, Waldbronn, Germany). Cisplatin was identified based on its characteristic retention time in hydrophilic interaction liquid chromatography (HILIC) using a ZIC Ò -HILIC column (dimensions 150 9 2.1 mm, particle size 3.5 lm) from SeQuant (Marl, Germany) and a mobile phase containing aqueous ammonium formate buffer (20 mM, SigmaAldrich Chemie GmbH, Steinheim, Germany) with a pH of 7.4 and methanol (Merck, Darmstadt, Germany). An isocratic flow of 60% methanol was used throughout. Proteins from the cell culture medium were precipitated with acetonitrile (Merck, Darmstadt, Germany) and separated by centrifugation prior to analysis.
Results
Since DCA was reported to decrease DWm in adult tumour cell lines already at concentrations of 0.5 mmol/L, we exposed 18 cell lines to seven 10-fold drug dilutions of DCA ranging from 10 nmol/L to 10 mmol/L and only observed a moderate reduction of cell viability at the highest test concentration (Fig. 1) . In the medulloblastoma cell lines DAOY and UW228.2, the rhabdomyosarcoma cell lines RD and RH-30, and the Ewing sarcoma cell line CADO-ES-1 DCA concentrations of 10 mmol/L attenuated cell viability by 30-50% compared to untreated controls. The DCA effects on cell viability were not related to the rate of cell growth during the time of drug exposure as estimated from the increase in cell viability of untreated controls. Since stimulation of the PDH and the Krebs cycle by PDK inhibition through DCA might at least in part counteract measurements of cell viability, which are based on the activity of mitochondrial aldehyde dehydrogenases and cellular ATP content, we also analysed induction of apoptosis by annexin V staining with comparable results. Just like in the cytotoxicity screens, DCA concentrations of 10 mmol/L only sparsely increased the rate of apoptotic cells. Increasing the dose to 50 mmol/L DCA raised the rate of apoptotic cells up to 80% (Fig. 2) . In accordance with the report of Bonnet et al., this effect was selective for the tumour cell lines, as DCA concentrations of 50 mmol/L failed to induce significant levels of phosphatidylserine externalisation in the non-malignant human embryonic kidney 293 cells (Fig. 2) . In addition, DCA reduced DWm in a dose-dependent manner. However, again exposure to DCA concentrations of 10 mmol/L for 72 h only reduced DWm in a small portion of cells. About 50% of cells were affected after an exposure to 25 mmol/L DCA for 72 h and DWm of all cells was decreased after exposure to 50 mmol/L DCA for 72 h (Fig. 3a-c) . At DCA concentrations of 50 mmol/L, a reduction of DWm was measurable already within 5 min in a small portion of cells. The rate of cells with reduced DWm increased after 24 h and after 48 h DWm of the whole cell population was reduced (Fig. 3d-f) . The reduction of DWm facilitates the release of pro apoptotic factors like cytochrome c and AIF, which in turn should facilitate apoptosis induced by standard anticancer drugs like cisplatin or doxorubicin. However, when combined with DCA, the cytotoxicity of cisplatin was reduced or even abolished in 7 out of 10 cell lines (Fig. 4) . The efficacy of cisplatin is based on the formation of an aquocomplex, which is responsible for the platination of DNA and proteins by nucleophiles. In order to exclude alleviation of cisplatin toxicity simply by chemical artefacts due to the high DCA concentrations used, we determined cisplatin concentrations in cell culture medium in the presence and the absence of DCA and found no differences between incubations with and without DCA (Fig. 5a ). In addition, the cellular uptake of platinum was not affected by DCA (Fig. 5b) . To determine whether DCA also alleviated the toxicity of other standard anticancer drugs, the cytotoxicity of doxorubicin and temozolomide alone and combined with DCA was analysed on the leukaemia cell lines MOLT-4 and CCRF-CEM. In these cell lines, DCA completely abolished the cytotoxicity of doxorubicin comparable to the DCA effect on cisplatin toxicity (Fig. 6a) . However, the cytotoxicity of temozolomide was neither reduced nor increased by combination with DCA (Fig. 6b) . In addition, DCA suppressed caspase 3/7 activation induced by cisplatin (Fig. 6c) and doxorubicin (Fig. 6d) . Interestingly, despite induction of phosphatidylserine externalisation as an early event in apoptosis and despite of reduction of DWm, DCA treatment alone failed to activate caspase 3/7. 
Discussion
The outstanding experiments of Bonnet et al. identifying DCA as selective anticancer drug attracted oncologists' and also patients' attention [6] [7] [8] [9] [10] [11] [12] . Though clinical trials in humans with cancer had yet to be performed and though accordingly DCA had not been approved for the treatment of cancer by FDA and EMA, it was celebrated as the magic bullet against cancer by the public press further stimulating the attraction of DCA for patients with cancer. Patients with cancer opt for this orally available drug and can purchase it from several distributors [16] . We evaluated the effects of DCA against paediatric malignancies in vitro and only found moderate effects of DCA. In line with the observations of Bonnet et al., DCA was able to selectively initiate apoptosis in paediatric tumour cell lines compared to non-malignant cells. However, high rates of phosphatidylserine externalisation and significant effects on DWm reduction were only measurable at concentrations of 25 mmol/L, while DCA concentrations of 10 mmol/L had little or no effect at all. This again was in line with the poor cytotoxic effects of DCA against paediatric tumour cell lines, which we observed at DCA concentrations up to 10 mmol/L. In contrast to some endometrial cancer cell lines, no significant increase in cell viability at low DCA concentrations was observed for the cell lines analysed in this study [7] . Some factors might be responsible for the poor effects of DCA observed in this study. First of all anaerobic glycolysis might be less important for the metabolism of the paediatric tumours types studied [17] . However, there are several lines of evidence (i.e. from fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET), gene and protein expression profiling) that paediatric tumours like adult tumours have a high glucose turnover and that anaerobic glycolysis might also be relevant for paediatric malignancies [18] [19] [20] [21] [22] . Furthermore, the expression of the four PDK isoforms and/or of antiapoptotic proteins, like Bcl-2, PUMA or survivin might have influenced the sensitivity to DCA [5, 7] . Especially the lack of caspase activation observed by us as well as Sun et al. might be attributed to over expression of antiapoptotic proteins [9] . Differences in the expression of Kv1.5 channels might also have discriminated between DCAsensitive and DCA-resistant cell lines, since activation of Kv1.5 channels by ROS results in a positive feedback loop, which promotes caspase activation [6] . Ongoing studies on the cell line-specific glycolytic phenotype along with the cell line-specific expression of the different PDK isoforms, Kv1.5 channels and antiapoptotic proteins will further clarify these issues. Tolerable DCA dosages of 25 mg/kg/d given twice daily, which were clinically applied for the treatment of mitochondrial disorders, resulted in peak plasma concentrations of 100-250 lmol/L after the first dose and 200-550 lmol/L after 6 month of therapy [23] .
Plasma concentrations of about 1 mmol/L were observed after the first application of 50 mg/kg DCA as well as after chronic exposure to 25 mg/kg DCA [15, 24] . Higher plasma concentrations would require higher dosages, whose tolerability has not been evaluated so far. This already argues against an unguarded use of DCA against cancer. Even more important is the fact that DCA was able to fade out the cytotoxicity of standard anticancer drugs. Making cancer cells more susceptible to apoptosis by selectively switching their glucose metabolism from anaerobic to aerobic glycolysis is challenging, since it promises better response of cancer cells to chemotherapy. Bonnet et al. observed a reduction of tumour size by DCA treatment in non-small-cell lung cancer xenografts but no complete remissions [6] , which, in addition, argues for the combination of DCA with other anticancer drugs. Dhar and Lippard addressed this issue and designed a new platinum drug, mitaplatin, which consists of one molecule cisplatin with two molecules DCA [25] . Within the cell mitaplatin is reduced and cisplatin and DCA are released. Mitaplatin was toxic against a panel of five mainly adult tumour cell lines, but failed to increase the cytotoxicity of cisplatin. On the contrary against some cell lines (U2OS or HeLa) the cytotoxicity of mitaplatin was decreased compared to cisplatin alone. We tested DCA and cisplatin at a molar ration of 1:100. This excess of DCA might have obliterated the toxicity of cisplatin due to chemical artefacts; however, neither intracellular platinum concentrations nor extracellular cisplatin concentrations were influenced by these high DCA concentrations. In addition, the cytotoxicity of doxorubicin, which in contrast to cisplatin exerts its 4 cells/well) were seeded and treated with DCA, cisplatin and doxorubicin as indicated. Caspase activation was analysed 24 h after drug exposure toxicity against tumour cells by inhibition of topoisomerase II and not by DNA modifications, was also attenuated by DCA. The toxicity of temozolomide, another DNA modifying agent, however, was not compromised by DCA at the drug concentrations tested. Standard anticancer drugs, like cisplatin, doxorubicin, and temozolomide exert their effects mainly on proliferating cells and concomitant inhibition of proliferation reduces the cytotoxicity of standard anticancer drugs. DCA was reported to inhibit cell proliferation [6] [7] [8] [9] [10] . The reduction of cell viability, which we observed in 5 out of 18 cell lines, might well be attributed to reduced cell proliferation. However, DCA reduced the cytotoxicity of cisplatin in DCA-sensitive as well as DCA-resistant cell lines suggesting that inhibition of proliferation by DCA was not responsible for the observed reduction of cisplatin toxicity by DCA. Apart from DNA, cisplatin and doxorubicin both impair mitochondrial function. One of the DCA-cisplatin and DCAdoxorubicin interaction sites could be the mitochondrial voltage-dependent anion channel (VDAC). The VDAC plays an important role in the inhibition of apoptosis, but is also part of the mitochondrial transition pore (MTP) as described earlier, a downstream target of DCA [26] . Interestingly, VDACs seem to be one main target of cellular proteins for cisplatin [27] . Convenient to this hypothesis is the fact that one of the main interaction sites in cells for doxorubicin is the mitochondrial membrane, including VDACs [28] . The finding that there was no effect of DCA to temozolomide-induced cell death adds further support to this hypothesis. To date, temozolomide is not known to interact with the mitochondria or the mitochondrial membrane. Further investigations on these interactions could help to decipher drug interactions between DCA and anticancer drugs, which in turn will help to develop optimal strategies for targeting the Warburg effect.
The Warburg effect is an interesting selective target for the treatment of cancer, however, our studies underline that targeting the Warburg effect for cancer treatment is far more complex than anticipated and more pre-clinical and clinical work is absolutely necessary to exclude any disadvantage for patients with cancer. Moreover, our observations strongly argue against compassionate use of DCA by patients with cancer themselves without medical supervision.
